Clinical research and clinical care move towards a more patient-centred approach in which health-related quality of life (HRQOL) and other patient-reported outcomes (PRO) play a central role. However, diverse ways of analysing PRO and HRQOL endpoints make it difficult to compare results across various cancer clinical trials. The hypothetical randomized trial presented illustrates this problem.

**INTRODUCTION**

Setting international standards in analysing patient-reported-outcomes and quality of life endpoints data for cancer clinical trials - SISAQOL Consortium

- **Main Objective:**
  - The Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium presents illustrates this problem.

**FUTURE STEPS**

As future step, we will broaden our scope towards other clinical trial designs and other types of PRO methods. The objective of the SISAQOL initiative is to provide freely available tools and guidance on international consensus standards for the analysis of PRO and HRQOL data from clinical trials. We hope these tools will instil familiarity with standardised reporting which will contribute to more reliable findings, better dissemination of data, higher quality use of statistical methods, and improved interpretability of data.

**ACKNOWLEDGMENTS**

EORTC received an unrestricted educational grant from Boehringer Ingelheim GmbH to initiate this work and additional financial support was provided by the EORTC Cancer Research Fund and Fonds Cancer (FCOA) from Belgium.

**REFERENCES**


Visit us at www.eortc.org/sisaqol